Drop in clinical trial numbers underscores drugmakers' fears over Brexit that trace back over a year
A week ago, Recardio announced it would cut UK trial sites out of its upcoming heart drug study citing Brexit fears that quickly reverberated across the industry. It turns out that the little biotech was merely following a trend that already emerged last year.
In 2017, a total of 597 trials were launched in Britain — 25% lower than the average between 2009-16, according to an analysis by Fitch. In those eight years, the average number of new clinical trials was 806.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.